Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17142029 | 0.79 | TRIM24 (0.41) | TRIM24TRIM33ALDH1A1BRD4BRD2 | |
| SCHEMBL3658220 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR | |
| SCHEMBL3558104 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR | |
| SCHEMBL6050831 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR | |
| SCHEMBL42220 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR | |
| SCHEMBL2807354 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR | |
| SCHEMBL6926105 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR | |
| SCHEMBL726729 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR | |
| SCHEMBL2457046 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR | |
| SCHEMBL14084740 | 0.73 | MGLL (0.40) | ALDH1A1HRH3POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170234883-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-6281352-B1 | ANTIINFLAMMATORY AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170234883-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | STXBP1, WASF2, SDAD1 | TRIM24 931/4885TRIM33 1994/4885ALDH1A1 3246/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TRIM24 2070/4885TRIM33 2605/4885ALDH1A1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.